Biopharma faces uncertainty in H2 2025 amid policy concerns and market challenges, with key healthcare conferences and ...

Sinema has backed a bill advancing in the Arizona legislature that would include a $5 million grant to a neurological ...

Youngblood has left Bristol Myers Squibb to join Acadia Pharmaceuticals as SVP of its rare disease franchise. She had a ...

Summit Therapeutics' ivonescimab shows 48% PFS benefit but misses OS endpoint in Phase 3 lung cancer trial; drug's regulatory ...

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Midi Health, the virtual care company best known for providing hormone therapy for women in menopause, is expanding to ...

The US Supreme Court will continue deciding whether to take up a pivotal case on state PBM regulation after the federal ...

Eisai and Merck succeeded in stopping Shilpa Medicare Ltd. from launching a generic version of Lenvima for at least another ...

As of Thursday morning, just over 300 entries out of at least 950 public comments have been released by the Department of ...

Sanofi partners in Vietnam, Almac hits £1B sales, Quadria raises $1.07B, CurifyLabs gets funding, BrainStorm signs with ...

The companies said Thursday that they voluntarily withdrew the accelerated approval request for patritumab deruxtecan in ...

After a slight delay, the FDA rejected Stealth BioTherapeutics' Barth syndrome drug application for elamipretide, but will ...